Intersect ENT Commences Public Offering

Public Offering of 3,000,000 Shares of Common Stock

MENLO PARK, Calif.--()--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the commencement of an underwritten public offering of 3,000,000 shares of its common stock to be sold by the company. In addition, the company expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock from the company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. Leerink Partners, Canaccord Genuity and William Blair are acting as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Copies of the registration statement, as amended, can be accessed through the SEC's website at www.sec.gov. The offering of these securities will be made only by means of a prospectus, copies of which, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by e-mail at prospectus-eq_fi@jpmchase.com, or by telephone at (866) 803-9204, or from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, or by e-mail at dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections and is one of the most costly conditions to U.S. employers.

XENT-F

Contacts

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
ir@intersectENT.com

Contacts

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
ir@intersectENT.com